Does the media refer more to CLNN or SNSE?

In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FRMM or SNSE more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Sensei Biotherapeutics N/A -83.59% -256.50%

Is ENTX or SNSE more profitable?

Entera Bio's return on equity of -83.31% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media refer more to ENTX or SNSE?

In the previous week, Entera Bio had 5 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Sensei Biotherapeutics. Entera Bio's average media sentiment score of 0.40 beat Sensei Biotherapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PLRX or SNSE more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts rate SNSE or XBIT?

Sensei Biotherapeutics presently has a consensus target price of $48.00, suggesting a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SNSE or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is SNSE or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% XBiotech N/A -26.10% -25.06%

Does the media favor SNSE or XBIT?

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 1 articles in the media. XBiotech's average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensei Biotherapeutics (SNSE) Competitors

$14.14 +0.30 (+2.13%)

Closing price 06/15/2026

Extended Trading

$14.14 0.00 (0.00%)

As of 06/15/2026 07:54 PM Eastern

Compare

SNSE vs. CLNN, FRMM, ENTX, PLRX, and XBIT

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include Clene (CLNN), Forum Markets (FRMM), Entera Bio (ENTX), Pliant Therapeutics (PLRX), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to Clene?

Clene (NASDAQ:CLNN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.3% of Clene shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Clene presently has a consensus price target of $33.25, indicating a potential upside of 479.27%. Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Clene's stronger consensus rating and higher possible upside, equities analysts plainly believe Clene is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sensei Biotherapeutics has lower revenue, but higher earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	366.79	-$26.17M	-$3.20	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Sensei Biotherapeutics has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Summary

Clene beats Sensei Biotherapeutics on 10 of the 12 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Forum Markets presently has a consensus target price of $10.00, indicating a potential upside of 97.24%. Sensei Biotherapeutics has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 15.1% of Forum Markets shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Forum Markets. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Forum Markets	Neutral
Sensei Biotherapeutics	Neutral

Sensei Biotherapeutics' return on equity of -83.59% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Sensei Biotherapeutics has lower revenue, but higher earnings than Forum Markets. Forum Markets is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	11.25	-$450.52M	-$36.07	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Forum Markets has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Summary

Forum Markets beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Entera Bio's return on equity of -83.31% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Entera Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Entera Bio has higher revenue and earnings than Sensei Biotherapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,897.67	-$11.44M	-$0.27	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

In the previous week, Entera Bio had 5 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Sensei Biotherapeutics. Entera Bio's average media sentiment score of 0.40 beat Sensei Biotherapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio presently has a consensus target price of $9.00, indicating a potential upside of 484.42%. Sensei Biotherapeutics has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Entera Bio's higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Entera Bio beats Sensei Biotherapeutics on 11 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Pliant Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Sensei Biotherapeutics	Neutral

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 8.0% of Pliant Therapeutics shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pliant Therapeutics' return on equity of -58.11% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Sensei Biotherapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.84	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 165.49%. Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Pliant Therapeutics beats Sensei Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to XBiotech?

Sensei Biotherapeutics (NASDAQ:SNSE) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 1 articles in the media. XBiotech's average media sentiment score of 0.67 beat Sensei Biotherapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics presently has a consensus target price of $48.00, suggesting a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XBiotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

XBiotech's return on equity of -26.10% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
XBiotech	N/A	-26.10%	-25.06%

Summary

XBiotech beats Sensei Biotherapeutics on 7 of the 11 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNSE vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.98M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-0.10	20.68	25.17	23.98
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.96	8.26	10.76	6.41
Net Income	-$21.08M	$23.91M	$3.56B	$337.14M
7 Day Performance	N/A	3.05%	1.37%	-0.48%
1 Month Performance	-20.49%	2.40%	0.81%	0.49%
1 Year Performance	67.00%	56.35%	30.53%	28.16%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNSE Sensei Biotherapeutics	2.7906 of 5 stars	$14.15 +2.1%	$48.00 +239.3%	+75.5%	$18.98M	N/A	N/A	40	Gap Up High Trading Volume
CLNN Clene	3.081 of 5 stars	$5.77 -2.0%	$33.25 +476.3%	+40.7%	$75.26M	$200K	N/A	100
FRMM Forum Markets	1.936 of 5 stars	$5.03 -2.5%	$10.00 +98.8%	N/A	$75.04M	$6.55M	N/A	7
ENTX Entera Bio	2.4018 of 5 stars	$1.55 +4.7%	$9.00 +480.6%	-21.1%	$72.95M	$40K	N/A	20	Analyst Forecast
PLRX Pliant Therapeutics	1.6602 of 5 stars	$1.16 flat	$3.00 +158.6%	-7.2%	$71.83M	$1.58M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNSE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. CLNN, FRMM, ENTX, PLRX, and XBIT

How does Sensei Biotherapeutics compare to Clene?

Summary

How does Sensei Biotherapeutics compare to Forum Markets?

Summary

How does Sensei Biotherapeutics compare to Entera Bio?

Summary

How does Sensei Biotherapeutics compare to Pliant Therapeutics?

Summary

How does Sensei Biotherapeutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. CLNN, FRMM, ENTX, PLRX, and XBIT

How does Sensei Biotherapeutics compare to Clene?

Which has more volatility & risk, CLNN or SNSE?

Does the media refer more to CLNN or SNSE?

Do institutionals & insiders believe in CLNN or SNSE?

Do analysts rate CLNN or SNSE?

Which has preferable valuation and earnings, CLNN or SNSE?

Is CLNN or SNSE more profitable?

Summary

How does Sensei Biotherapeutics compare to Forum Markets?

Do analysts prefer FRMM or SNSE?

Do institutionals and insiders believe in FRMM or SNSE?

Does the media prefer FRMM or SNSE?

Is FRMM or SNSE more profitable?

Which has better earnings and valuation, FRMM or SNSE?

Which has more risk & volatility, FRMM or SNSE?

Summary

How does Sensei Biotherapeutics compare to Entera Bio?

Is ENTX or SNSE more profitable?

Which has more risk and volatility, ENTX or SNSE?

Do institutionals & insiders believe in ENTX or SNSE?

Which has higher earnings & valuation, ENTX or SNSE?

Does the media refer more to ENTX or SNSE?

Do analysts rate ENTX or SNSE?

Summary

How does Sensei Biotherapeutics compare to Pliant Therapeutics?

Which has more volatility and risk, PLRX or SNSE?

Does the media refer more to PLRX or SNSE?

Do institutionals and insiders believe in PLRX or SNSE?

Is PLRX or SNSE more profitable?

Which has preferable valuation & earnings, PLRX or SNSE?

Do analysts rate PLRX or SNSE?

Summary

How does Sensei Biotherapeutics compare to XBiotech?

Do institutionals and insiders believe in SNSE or XBIT?

Which has more risk & volatility, SNSE or XBIT?

Does the media favor SNSE or XBIT?

Do analysts rate SNSE or XBIT?

Which has better earnings & valuation, SNSE or XBIT?

Is SNSE or XBIT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools